Z Radical Contains Carbon To Carbon Unsaturation Patents (Class 514/549)
-
Patent number: 8324195Abstract: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.Type: GrantFiled: January 12, 2012Date of Patent: December 4, 2012Assignee: Amarin Pharmaceuticals Ireland LimitedInventors: Mehar Manku, Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni
-
Publication number: 20120302589Abstract: The present invention relates to, inter alia, pharmaceutical compositions comprising EPA and one or more cardiovascular agents, and to therapeutic methods for treating various diseases and disorders using the same.Type: ApplicationFiled: March 12, 2012Publication date: November 29, 2012Applicant: Amarin Pharma, Inc.Inventors: Mehar Manku, Jonathan Rowe
-
Patent number: 8318715Abstract: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.Type: GrantFiled: October 26, 2011Date of Patent: November 27, 2012Assignee: Amarin Pharmaceuticals Ireland LimitedInventors: Mehar Manku, Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni
-
Patent number: 8314086Abstract: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.Type: GrantFiled: October 28, 2011Date of Patent: November 20, 2012Assignee: Amarin Pharmaceuticals Ireland LimitedInventors: Mehar Manku, Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni
-
Publication number: 20120277308Abstract: This invention provides a method of synthesizing new active compounds for pharmaceutical uses including cancer treatment, wherein the cancers comprise breast, leukocytic, liver, ovarian, bladder, prostatic, skin, bone, brain, leukemia, lung, colon, CNS, melanoma, renal, cervical, esophageal, testicular, spleenic, kidney, lymphatic, pancreatic, stomach and thyroid cancers. This invention is an anti adhesion therapy which uses the compound as a mediator or inhibitor of adhesion proteins and angiopoietins. It inhibits excess adhesion and inhibits cell attachment. It modulates angiogenesis. The compounds also use as mediator of cell adhesion receptor, cell circulating, cell moving and inflammatory diseases.Type: ApplicationFiled: July 15, 2011Publication date: November 1, 2012Applicant: PACIFIC ARROW LIMITEDInventors: Pui-Kwong Chan, May Sung Mak
-
Publication number: 20120277316Abstract: Methods and compositions for treating or preventing parenteral nutrition associated liver disease are provided. Methods and compositions for advancing enteral tolerance in subjects receiving enteral nutrition are provided. The methods involve the use of omega-3 fatty acid compositions. In some embodiments the omega-3 fatty acid compositions comprise docosahexanoic acid and eicosapentaenoic acid. In some embodiments the omega-3 fatty acid compositions comprise fish oil. In some embodiments the subjects to be treated are receiving parenteral nutrition. In some embodiments the subjects to be treated are infants having a low birth weight, very low birth weight, extremely low birth weight, a low gestational age, short bowel syndrome, necrotizing entercolitis, or any combination thereof.Type: ApplicationFiled: January 19, 2011Publication date: November 1, 2012Inventors: Emma Tillman, Richard A. Helms, Michael Storm
-
Publication number: 20120277317Abstract: A method for the treatment and/or prevention of amyloidos-related diseases, such as for example Alzheimer's disease and IgA nephropathy, comprising administering to a human or an animal a composition comprising at least (all-Z omega-3)-4,7,10,13,16,19-docosahexaenoic acid (DHA) is provided.Type: ApplicationFiled: June 21, 2012Publication date: November 1, 2012Inventors: Morten BRYHN, Knut Sletten, Gunilla Torstensdotter Westermark, Per Olof Westermark
-
Publication number: 20120277311Abstract: Compounds having the active site of natural lipoxins, but a longer tissue half-life are disclosed. In particular, 15-epi-lipoxins and their use in ameliorating undesired cell proliferation, which characterizes diseases such as cancer, are also disclosed.Type: ApplicationFiled: October 21, 2010Publication date: November 1, 2012Inventor: Charles N. Serhan
-
Publication number: 20120270944Abstract: Semiochemicals are combined with oils and/or antioxidants in order to control and maintain the necessary threshold release rates of the semiochemicals (such as attractants or repellents) from release devices for optimal activity/performance, for the reduction or elimination of semiochemical oxidation, isomerization, breakdown and polymerization, and also for stabilizing and/or protecting the active semiochemical ingredients.Type: ApplicationFiled: April 26, 2012Publication date: October 25, 2012Applicant: STERLING INTERNATIONAL INC.Inventors: Qing-He Zhang, Rodney G. Schneidmiller
-
Patent number: 8293278Abstract: Compositions, methods for forming compositions, and methods for using compositions for reducing tadpole shrimp populations in temporary pools using the hormone methyl farnesoate. Compositions can include a dry base having a bulk ingredient, a viscous additive having an oily compound, a saline solution, and preparation having an effective amount of phospholipid-encapsulated methyl farnesoate. The composition can be formed by combining the dry base and the viscous additive into a first mixture and adding all or a portion of the saline solution to form a crumbly consistency. Then, the methyl farnesoate preparation can be added. The composition may then be formed into a plurality of particles having shapes and sizes for consumption by the tadpole shrimp. In use, the particles may be dispensed prior to, or immediately after, the temporary pools are flooded with water. The particles may be formed such that they can withstand exposure to water for between about 4 to about 14 days.Type: GrantFiled: November 16, 2009Date of Patent: October 23, 2012Assignee: Fresno California State UniversityInventor: Brian K C Tsukimura
-
Patent number: 8293790Abstract: The present disclosure provides compositions comprising fatty acids, or derivatives thereof (e.g., C1-C4 esters) including, for example, DGLA, 15-OHEPA and/or 15-HETrE, used singly or in combination with anti-bacterial agents for the treatment of disease and/or disorders such as acne or atopic dermatitis.Type: GrantFiled: May 23, 2012Date of Patent: October 23, 2012Assignee: Dignity Sciences LimitedInventors: Mehar Manku, John Climax, David Coughlan
-
Patent number: 8293727Abstract: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.Type: GrantFiled: February 9, 2010Date of Patent: October 23, 2012Assignee: Amarin Pharmaceuticals Ireland LimitedInventors: Mehar Manku, Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni
-
Patent number: 8293728Abstract: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.Type: GrantFiled: January 12, 2012Date of Patent: October 23, 2012Assignee: Amarin Pharmaceuticals Ireland LimitedInventors: Mehar Manku, Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni
-
Publication number: 20120265119Abstract: The use of phonophoresis or iontophoresis to enhance transdermal delivery of medicinal Cetylated fatty esters when applied in cream or gel compositions is disclosed. These compositions provide hydrophilic salt forms and penetration-enhancing vehicles that work in conjunction with phonophoresis or iontophoresis to increase the efficacy of the medicinal actives.Type: ApplicationFiled: March 16, 2011Publication date: October 18, 2012Applicant: CYMBIOTICS, INC.Inventors: Raj R. Barathur, Jack Bain Bookout
-
Publication number: 20120264824Abstract: Methods and compositions are disclosed comprising ethyl eicosapentanoate for the treatment of non-alcoholic steatohepatitis (NASH).Type: ApplicationFiled: April 15, 2011Publication date: October 18, 2012Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.Inventors: Kiyoshi MIZUGUCHI, Tsuyoshi Harada
-
Publication number: 20120255502Abstract: A method of treatment and a package that is designed to accomplish this. The package provides the pet owner with a pack containing individual doses of topically applied medications pre-packaged with an oral taste treat. The topically applied medication contains at least one pharmaceutically active ingredient selected from the group of chemical families comprising phenylpyrazoles, macrocyclic lactones, neonicotinoids, synthetic pyrethroids, insect growth regulators, amidines, semicarbazones, spinosyns, octadepsipeptides, and pyrazinoisoquinolines, or any combination thereof. The treat can be administered either before the topically applied treatment is given so as to relax and distract the pet, or after the treatment is given so as to reward the pet and help it forget the stress of treatment. The treat can also be shaped to signify the type of animal to be treated.Type: ApplicationFiled: March 29, 2012Publication date: October 11, 2012Applicant: ALLEVA ANIMAL HEALTH LIMITEDInventor: Robert HOLMES
-
Publication number: 20120251483Abstract: Provided are methods of treating cardiac infarction by using an injectable material to influence cardiac structure and remodeling after infarction. Also provided are kits that comprise an injectable material to influence cardiac structure.Type: ApplicationFiled: March 27, 2012Publication date: October 4, 2012Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: Jason A. Burdick, Robert C. Gorman, Joseph H. Gorman, III, Jamie L. Ifkovits
-
Patent number: 8273792Abstract: (Neuro)protectin D1 (1OR,17S-dihydroxy-docosa-4Z,7Z,11E,13E,15Z,19Z-hexaenoic acid) and 15,16-dehydro-PD1 and their derivatives are useful in the treatment of airway inflammation, especially asthma.Type: GrantFiled: October 3, 2006Date of Patent: September 25, 2012Assignees: The Brigham and Women's Hospital, Inc., The University of Southern CaliforniaInventors: Charles N. Serhan, Nicos A. Petasis, Bruce D. Levy
-
Publication number: 20120237594Abstract: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereofType: ApplicationFiled: May 29, 2012Publication date: September 20, 2012Applicant: AMARIN PHARMACEUTICALS IRELAND LIMITEDInventors: Mehar Manku, Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni
-
Patent number: 8268885Abstract: The present invention relates to small molecules as entry inhibitors of the HIV virus, processes for their preparation as well as pharmaceutical compositions, their use as medicines, and diagnostic kits comprising them. The present invention also concerns combinations of the present entry inhibitors with other anti-retroviral agents. It further relates to their use in assays as reference compounds or as reagents. The compounds of the present invention are useful for preventing or treating infection by HIV and for treating AIDS.Type: GrantFiled: September 10, 2004Date of Patent: September 18, 2012Assignee: Janssen R&D IrelandInventors: Koenraad Lodewijk August Van Acker, Piet Tom Bert Paul Wigerinck, Lieve Emma Jan Michiels, Abdellah Tahri
-
Publication number: 20120231077Abstract: A tablet comprising a tabletted core comprising a triglyceride granulate, and an enteric coating surrounding said tabletted core. In particular, a tablet wherein the tabletted core contains esterified omega-3 fatty acids such as eicosapentaenoic acid and/or docosahexaenoic acid.Type: ApplicationFiled: October 27, 2011Publication date: September 13, 2012Applicant: SPORTSCOM DANMARK APSInventors: Peter B. Samuelsen, Leif Knudsen, Kern Lystrup
-
Publication number: 20120232143Abstract: The present invention relates to lipid compounds of the general formula (I): wherein —R1 and R2 are the same or different and may be selected from a group of substituents consisting of a hydrogen atom, an alkyl group, a halogen atom, and an alkoxy group; —X is COR3 or CH2OR4, wherein —R3 is selected from the group consisting of hydrogen, hydroxy, alkoxy, and amino, —wherein X further comprises carboxylic acid derivatives when R3 is hydroxyl; and —R4 is selected from the group consisting of hydrogen, alkyl or acyl, —Y is a C9 to C21 alkene with one or more double bonds with E or Z configuration; or any pharmaceutically acceptable complex, solvate or pro-drug thereof. The present invention also relates to pharmaceutical compositions comprising such lipid compounds, and to such lipid compounds for use as medicaments or for diagnostic purposes.Type: ApplicationFiled: March 15, 2012Publication date: September 13, 2012Inventor: Anne Kristin HOLMEIDE
-
Publication number: 20120225120Abstract: The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.Type: ApplicationFiled: April 27, 2012Publication date: September 6, 2012Applicant: AMARIN PHARMACEUTICALS IRELAND LIMITEDInventors: Mehar Manku, Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni
-
Publication number: 20120225941Abstract: One embodiment described herein is related to methods and compositions, such as nutraceutical formulations and dietary supplements, comprising C16:1n7-palmitoleate or derivatives thereof. The methods and compositions comprising C16:1n7-palmitoleate, or derivatives thereof, safely and effectively prevent or mitigate manifestations of cardiovascular disease, including coronary artery disease and the accumulation of cholesterol or lipid deposits in the blood vessels of a subject.Type: ApplicationFiled: March 2, 2012Publication date: September 6, 2012Inventor: Jeffrey Green
-
Patent number: 8258184Abstract: A vegetable butter based dietary supplement of cetyl myristoleate for use in the treatment of osteoarthritis and other joint inflammatory diseases of the musculoskeletal system in animals, especially equines. In its preferred form, the cetyl myristoleate is a vegetable butter-based and is administered in doses of about 1750 to about 6750 mg. The dosage may also include 3000 mg methylsulfonylmethane, 3000 mg glucosamine HCL and 1000 mg of Vitamin C.Type: GrantFiled: June 25, 2010Date of Patent: September 4, 2012Assignee: Botanoceuticals, Inc.Inventors: Edward C. Leonard, Dori Simonton
-
Publication number: 20120220454Abstract: Coating compositions and methods of use, allowing for improved water and/or nutrient usage by seeds, plants, shrubs, and vegetation, among others, are disclosed.Type: ApplicationFiled: February 28, 2012Publication date: August 30, 2012Applicant: RHODIA OPERATIONSInventors: Zhiyun Chen, Jean-Christophe Castaing, PengFei JI, Galder Cristobal
-
Publication number: 20120214755Abstract: Methods for producing a composition that includes an active agent, nutraceutical and pharmaceuticals compositions, and methods for ameliorating and/or treating a disease using the composition that includes an active substance are described herein. More particularly, methods for producing a composition that contains one or more active substances such as oleocanthal, pharmaceutical compositions that include one or more active substances such as oleocanthal, and methods of ameliorating and/or treating inflammation using compositions that contains one or more active substances such as oleocanthal are described.Type: ApplicationFiled: February 17, 2012Publication date: August 23, 2012Inventor: Erwin Denk
-
Publication number: 20120213823Abstract: There are provided various compounds and compositions comprising polyunsaturated fatty acid monoglycerides and derivatives thereof. These compounds and compositions can be useful as cancer chemopreventive agents. They can also be useful for enhancing solubility of various active agents and enhancing their bioavailability.Type: ApplicationFiled: April 30, 2012Publication date: August 23, 2012Inventor: Samuel FORTIN
-
Publication number: 20120208884Abstract: There are provided various compounds and compositions comprising polyunsaturated fatty acid monoglycerides and derivatives thereof. These compounds and compositions can be useful as cancer chemopreventive agents. They can also be useful for enhancing solubility of various active agents and enhancing their bioavailability.Type: ApplicationFiled: April 30, 2012Publication date: August 16, 2012Inventor: Samuel FORTIN
-
Patent number: 8242172Abstract: The invention is directed to novel pharmaceutical compositions comprising chemicals agents that are useful in the treatment and prevention of cystic fibrosis and the prevention of signs and symptoms of this disease. These pharmaceutical compositions are surprisingly successful in the treatment disorders related to cystic fibrosis including disorders of blood production. Many of these compositions of the invention are even more effective when administered to a patient in pulses. Pulse therapy is not a form of discontinuous administration of the same amount of a composition over time, but comprises administration of the same dose of the composition at a reduced frequency or administration of reduced doses.Type: GrantFiled: July 14, 2010Date of Patent: August 14, 2012Assignee: Trustees of Boston UniversityInventor: Susan P. Perrine
-
Patent number: 8236855Abstract: A method of increasing the insulin sensitivity of insulin resistant cells includes administering to the cells an amount of all-trans-retinoic acid effective to activate transcription factor perosixome proliferator-activated receptor (PPAR) ?/? of the cells.Type: GrantFiled: May 19, 2008Date of Patent: August 7, 2012Assignee: Case Western Reserve UniversityInventor: Noa Noy
-
Publication number: 20120195963Abstract: A pharmaceutical preparation comprising EPA in an appropriately assimilable form where of all the fatty acids present in the preparation at least 90%, and preferably at least 95%, is in the form of EPA and where less than 5%, and preferably less than 3%, is in the form of DHA is provided.Type: ApplicationFiled: April 4, 2012Publication date: August 2, 2012Applicant: AMARIN PHARMACEUTICALS IRELAND LIMITEDInventors: Malcolm Peet, Krishna S. Vaddadi
-
Patent number: 8226963Abstract: The present invention provides lignin-pesticide complexes, methods for making lignin-pesticide complexes, and methods for treating or controlling insect infestations on animals by administering such complexes. Advantageously, the lignin-pesticide complexes of the present invention can be used in feed-through products to control insect infestation on livestock or pets. Various insects such as face flies, house flies, stable flies, and horn flies can be controlled and treated using the feed-through products of the present invention.Type: GrantFiled: September 26, 2006Date of Patent: July 24, 2012Assignee: Wellmark InternationalInventors: Kim W. Yang, Dennis Lee Murphy, Casey Shane White, Maria N. Parfenova, Joe Doyle McDaniel, Jinren Ko
-
Publication number: 20120184513Abstract: The invention relates to organic compounds having the ability to reduce or suppress the onset of skin irritation induced by extraneous cause selected from the group of 2-heptylcyclopentanone, 2-ethoxynaphthalene; 2-methoxynaphthalene; 1-methoxy-4-(prop-1-enyl)benzene; 1-(cyclopropylmethyl)-4-methoxybenzene; wherein X, Y, and R1 to R11 have the same meaning as given in the description. Furthermore the invention refers to compositions for topical application to the skin comprising them. It further relates to a method of reducing or suppressing the formation of skin irritation.Type: ApplicationFiled: January 14, 2011Publication date: July 19, 2012Applicant: Givaudan SAInventors: Andreas NATSCH, Michael WASESCHA
-
Publication number: 20120184441Abstract: The present invention relates to an oil-in-water emulsion, comprising oily globules that include at least one agriculturally active ingredient, in which the oily globules of the emulsion and are coated with a polymeric adsorption layer. The polymeric adsorption layer coating the oily globules includes (1) at least one polymeric surface-active agent having an HLB values in the range of about 16 to about 18, and (2) at least one ionic surface-active agent. The oily globules of the emulsion have mean particle diameter of less than about 800 nanometers, are resistant to Ostwald ripening and are well suited for the treatment of plants. Agriculturally active ingredients that can be used with the emulsion include, pesticides, herbicides, fungicides, mitocides, bactericides and the like. The invention further includes methods of using the inventive oil-in-water emulsions to treat plants and on surfaces adjacent to plants, plant pests or other pests.Type: ApplicationFiled: January 12, 2012Publication date: July 19, 2012Applicant: Dow Agrosciences LLCInventors: David G. Ouse, Holger Tank, Wen Xu
-
Patent number: 8222295Abstract: There are provided various compounds and compositions comprising polyunsaturated fatty acid monoglycerides and derivatives thereof. These compounds and compositions can be useful as cancer chemopreventive agents. They can also be useful for enhancing solubility of various active agents and enhancing their bioavailability.Type: GrantFiled: August 5, 2009Date of Patent: July 17, 2012Assignee: Centre de Recherche sur les Biotechnologies MarinesInventor: Samuel Fortin
-
Publication number: 20120172431Abstract: The present invention provides highly purified omega-3 fatty acid formulations. Certain formulations provided herein have contain greater than 85% omega-3 fatty acids by weight. Certain other formulations provided herein contain EPA and DHA in a ratio of from about 4.01:1 to about 5:1. The invention also provides methods of using the dosage forms to treat a variety of cardiovascular, autoimmune, inflammatory, and central nervous system disorders by administering a formulation of the invention to a patient in need thereof.Type: ApplicationFiled: December 5, 2011Publication date: July 5, 2012Applicant: CENESTRA LLCInventors: Seth D. Feuerstein, Ann CORIC, Louis C. Sanfilippo
-
Publication number: 20120172432Abstract: The present invention relates to, inter alia, pharmaceutical compositions comprising EPA and one or more cardiovascular agents, and to therapeutic methods for treating various diseases and disorders using the same.Type: ApplicationFiled: March 13, 2012Publication date: July 5, 2012Applicant: AMARIN PHARMA, INC.Inventors: Mehar Manku, Jonathan Rowe
-
Publication number: 20120156296Abstract: This invention relates to antioxidants and combinations of antioxidants used to prevent oxidation of pharmaceutical and nutraceutical products in the form of powders, granulates, tablets, emulsions, gels and the like comprising one or more fatty acids and/or fatty acid derivatives and, optionally, at least one carbohydrate carrier alone or together with vitamins, minerals and/or pharmaceuticals. In particular, the invention concerns the use of antioxidants to reduce oxidation of powders, tablets, gels and emulsions comprising high concentrations and high doses of omega-3 fatty acids or derivatives thereof.Type: ApplicationFiled: December 21, 2011Publication date: June 21, 2012Applicant: OMEGATRI ASInventors: Trine-Lise Torgersen, Jo Klaveness, Astrid Hilde Myrset
-
Publication number: 20120156285Abstract: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereofType: ApplicationFiled: February 23, 2012Publication date: June 21, 2012Applicant: AMARIN PHARMA, INC.Inventors: Mehar Manku, Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni
-
Publication number: 20120149771Abstract: The use of lipoxin analogs for the treatment or prevention of asthma and asthma related diseases is described. In particular, acetylenic lipoxin analogs are effective for the treatment and prevention of eosinophil recruitment involved with the inflammation processes associated with asthma, asthma like conditions, and lung injuries associated from airway inflammation or infection as brought about by leukocyte-mediated injury from within.Type: ApplicationFiled: February 21, 2012Publication date: June 14, 2012Applicant: The Brigham and Women's HospitalInventors: Charles N. Serhan, Bruce D. Levy
-
Patent number: 8198324Abstract: There are provided various compounds and compositions comprising polyunsaturated fatty acid monoglycerides and derivatives thereof. These compounds and compositions can be useful as cancer chemopreventive agents. They can also be useful for enhancing solubility of various active agents and enhancing their bioavailability.Type: GrantFiled: August 6, 2009Date of Patent: June 12, 2012Assignee: Centre de Recherche sur les Biotechnologies MarinesInventor: Samuel Fortin
-
Publication number: 20120142774Abstract: An emulsifying preparation for an oil-soluble component, which is sensorily superior when applied to an aqueous phase, can maintain stability for a long time, and imposes less restriction for formulation or production is provided. The emulsifying preparation of the present invention contains (A) an oil phase component containing an oil-soluble component, (B) an aqueous phase component containing a polyol, and (C) an emulsifier containing polyglycerol fatty acid monoester having an average degree of polymerization of not less than 10, and having an HLB value of not less than 14 and not more than 18 or showing a transmittance of 1 wt % aqueous solution at 600 nm of not less than 80%.Type: ApplicationFiled: December 5, 2011Publication date: June 7, 2012Applicant: AJINOMOTO CO. INCInventors: Yoko SHIMAGAMI, Yasushi Ichimi
-
Publication number: 20120142775Abstract: A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a lipid glyceride comprising a glycerol moiety and a fatty acid moiety, the fatty acid moiety being selected from the group consisting of ?-linolenic acid, dihomo-?-linolenic acid and arachidonic acid characterised in that the selected fatty acid moiety is attached to the glycerol moiety at its sn-2 position. Preferably the method is that wherein the lipid is administered for a duration and at a dose sufficient to maintain or elevate TGF-?1 levels in the patient to therapeutic levels.Type: ApplicationFiled: February 1, 2012Publication date: June 7, 2012Applicant: BTG International LimitedInventors: Laurence S. Harbige, Michael J. Leach, Mohammed Sharief, Paul Barraclough
-
Publication number: 20120136053Abstract: This invention relates to an oil composition, preferably obtained from a copepod, and the use thereof to reduce accumulation of visceral fat and counteract impairment of heart function caused by obesity inducing Western diets. The oil composition of the present invention can thus be used to reduce abdominal obesity and improve glucose tolerance and thus to reduce the risk of obesity related diseases such as but not limited to type 2 diabetes or cardiovascular disease, or to prevent or treat such diseases.Type: ApplicationFiled: June 11, 2010Publication date: May 31, 2012Applicant: CALANUS ASInventors: Jan Raa, Gunnar Rorstad, Kurt Steinar Tande
-
Publication number: 20120128724Abstract: Systems and methods for treating inflammatory and proliferative diseases, and wounds, using as a pharmacon a fatty acid metabolism inhibitor, a glycolytic inhibitor, and/or an agent able to alter cellular production of reactive oxygen, or combination thereof, optionally in combination with one or more chemotherapeutic agents. In preferred embodiments, the invention combines an oxirane carboxylic acid, represented by etomoxir, with a 2-deoxyglucose compound, represented by 2-deoxy-D-glucose, and/or an antibody against UCP and/or Fas antigen. The systems and methods of the invention can be used to treat drug-resistant or multi-drug resistant cancers.Type: ApplicationFiled: November 22, 2011Publication date: May 24, 2012Applicant: The Regents of the University of Colorado, a body corporateInventors: M. Karen Newell, Evan Newell, Elizabeth Villalobos-Menuey
-
Publication number: 20120129934Abstract: The present invention relates to the diagnosis, risk assessment, prevention, and treatment of Senile Dementia of the Alzheimer's Type (SDAT). More specifically the present invention relates to the measurement of ethanolamine phospholipids in human serum. Subsets of these molecules are significantly altered in subjects with pathologically confirmed deposits of ?-amyloid versus subjects without ?-amyloid deposits and in subjects with a clinical manifestation of dementia consistent with a diagnosis of SDAT versus non-demented controls. Further, the invention relates to the diagnosis of various stages of SDAT, the early detection and prevention of SDAT symptoms, the treatment of SDAT, the differential diagnosis of non-SDAT dementia, and the identification of molecular targets for which chemical or biological treatments can be designed for the therapeutic intervention of SDAT.Type: ApplicationFiled: August 27, 2007Publication date: May 24, 2012Applicant: PHENOMENOME DISCOVERIES INC.Inventor: Dayan Burke Goodenowe
-
Publication number: 20120128618Abstract: A cosmetic cleaning and care agent having good foaming properties includes a) at least one mild anionic surfactant and at least one mild amphoteric/dipolar ionic surfactant, wherein the total quantity of mild anionic and mild amphoteric/dipolar ionic surfactant is 3 to 20% by weight, b) 0.005 to 5% by weight of at least one non-ionic cellulose ether, and c) 0.005 to 5% by weight of at least one non-ionic polymer of the formula (I), where R stands for a hydrogen atom or methyl group, and n stands for an average value of 10 to 1200.Type: ApplicationFiled: January 27, 2012Publication date: May 24, 2012Applicant: Henkel AG & Co, KGaAInventors: Marcus Claas, Bernhard Banowski
-
Publication number: 20120128770Abstract: The present invention relates to 1 or 2 C16-C18 acyl glycerol based compounds which are capable of activating G-protein coupled receptor 119 and thereby stimulate GLP-1 release. Compounds of the present invention are useful in the prophylaxis and/or treatment of metabolic disorders and complications thereof, such as, type 2 diabetes mellitus (T2DM), obesity, insulin resistance, and cardiovascular disease.Type: ApplicationFiled: June 24, 2010Publication date: May 24, 2012Applicant: Kobenhavns UniversitetInventors: Harald S. Hansen, Thi Ai Diep, Jens Juul Holst, Mette Marie Rosenkilde, Niels Wellner Andersen
-
Publication number: 20120128763Abstract: A formulation has been developed for treatment of the symptoms of dry eye which incorporates the natural product jojoba wax, or components thereof, to enhance the spreading of the artificial tear and eyedrop as well as stabilize the eyedrop. The improved performance of the jojoba wax supplemented tear relieves irritation and discomfort as well as sharpens the blurred vision.Type: ApplicationFiled: February 2, 2012Publication date: May 24, 2012Inventor: Steven Maskin